Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868615 · ClinicalTrials.gov registry record · NA
AVAVA MIRIA General Use
A NA study of Acne and Wrinkle, sponsored by AVAVA.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06868615: Recruiting NA study of Acne and Wrinkle, sponsored by AVAVA.
NCT06868615 is a NA study of Acne and Wrinkle that is actively recruiting participants, run by AVAVA. The registered enrollment target is 200 participants, above the 135-participant average among 26 other Acne trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06868615, a NA study of Acne and Wrinkle, is actively recruiting participants, sponsored by AVAVA.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
A general protocol to treat a variety of dermatologic conditions and collect patient feedback. Primary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment. Secondary outcome measures include physician and subject evaluations in regards to improvement seen in the device as well as assessment of side effects.
Primary Outcome
Post-treatment questionnaire to evaluate the overall patient experience including descriptions of the treatment session and overall patient experience.
Conditions Studied
Interventions
- DEVICE AVAVA
Study Locations (1)
Massachusetts
- AVAVA, Inc. - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2027-12-30 |
| Phase | NA |
What NCT06868615 shows while recruiting
NCT06868615 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 135-participant average among 26 other Acne trials with a reported enrollment target (48% higher).
The record links to 6 conditions, with Acne appearing as the primary indexed condition, and to 1 intervention - of which AVAVA is the first listed.
NCT06868615 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06868615 about?
NCT06868615 is a clinical study titled "AVAVA MIRIA General Use". A general protocol to treat a variety of dermatologic conditions and collect patient feedback. Primary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment. Secondary outcome measures include physician and subject evaluations in ...
What is the current status of trial NCT06868615?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-09-11. Estimated completion is 2027-12-30.
What conditions does trial NCT06868615 study?
This clinical trial studies the following conditions: Acne, Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic, Scars, Pigment; Lesion.
What interventions are being tested in trial NCT06868615?
The interventions under investigation include: AVAVA (DEVICE).
Who is sponsoring clinical trial NCT06868615?
This trial is sponsored by AVAVA, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868615 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06868615's enrollment target sits among peer trials
200 5th of 26 higher than 22 of 26 other Acne trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
ACTIVE NOT RECRUITING · NA
-
The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation
COMPLETED · NA
-
An Exploratory Investigation of a Male Focused Skincare Supplement
COMPLETED · NA
-
An Exploratory Investigation of a Novel Skincare Regimen
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI